GLP-1 drugs like Ozempic and Wegovy offer surprising benefits beyond weight loss, but also carry unexpected risks.

After accounting for 14% of all prescription drug spending in 2025, the blockbuster GLP-1 drug class is on track to continue rapid growth and alter pharmaceutical spending trends.  For example, Eli ...

Researchers sought to determine whether GLP-1 receptor agonists affected 10-year mortality and recurrence-free survival in patients with breast cancer.

New research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that ...

Ozempic promotes weight loss by mimicking the GLP-1 hormone the body naturally produces after eating, so users feel full for longer. This new potential therapy harnesses the power of GLP-1 while ...

A pair of trial results published in medical journals suggest switching from high-dose injectables to lower doses or pills could help people with obesity keep their weight down over the long term.

India's metabolic burden is rising; T2DM prevalence, BMI, and cholesterol are all worsening. With the loss of injectable semaglutide exclusivity in India, generic competition promises ...

Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to a new RAND report. Subscribe to our newsletter for the latest sci-tech ...

Eli Lilly said its tirzepatide franchise had another stellar quarter.

GLP-1 use isn't just drastically changing the lives of those, like McDonald, who are on the weight-loss drug. It's changing ...